NHC Comments on Medical Device User Fee Amendments Performance Goals and Procedures for Fiscal Years 2028 through 2032 August 6, 2026 Dockets Management Staff Food and Drug Administration 5630 Fishers […]
FDA regulations
NHC Submits Statement for the Record to Senate Budget Committee on Medicaid
NHC Submits Statement for the Record to Senate Budget Committee on Medicaid Prepared Written Testimony Randall Rutta Chief Executive Officer National Health Council U.S. Senate, Committee on the Budget August 4, 2026 On […]
NHC Comments on Medicaid Program Community Engagement Requirements
NHC Comments on Medicaid Program Community Engagement Requirements July 31, 2026 Mehmet Oz, MD, MBA AdministratorCenters for Medicare & Medicaid Services Department of Health and Human Services 7500 Security BoulevardBaltimore, […]
NHC Comments on FDA – Pharmacy Compounding Advisory Committee Meeting on Bulk Drug Substances for Section 503A
NHC Comments on FDA – Pharmacy Compounding Advisory Committee Meeting on Bulk Drug Substances for Section 503A July 22, 2026 Dockets Management Staff (HFA-305) Food and Drug Administration 5630 Fishers […]
NHC Responds to FDA RFI on Drug Repurposing
NHC Responds to FDA RFI on Drug Repurposing June 11, 2026 Acting Commissioner of Food and Drugs U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 RE: […]
Integrated Assessment of Marketing Applications Virtual Workshop
The Honorable Stephen Hahn Commissioner U.S. Food and Drug Administration Food and Drug Administration Dear Commissioner Hahn: On behalf of the National Health Council (NHC), I am pleased to provide the following comments […]
NHC Commitment to Ensure Representativeness in all Policy Work
By Maddie Mason, Senior Associate, Policy The National Health Council (NHC) has pledged to ensure that our policy work is inclusive and representative of all populations. In our comment and policymaking opportunities, we are particularly committed to this, and strive to have our policy work directly reflect […]
NHC Comments on PDUFA VII Public Stakeholder Meeting
By Maddie Mason, Senior Associate, Policy The National Health Council (NHC) submitted comments last week to the Food and Drug Administration (FDA) on their July 23 Public Stakeholder Meeting on the Prescription Drug User Fee Act (PDUFA) VII where NHC […]
Reauthorization of the Prescription Drug User Fee Act
The National Health Council (NHC) appreciates the opportunity to provide a response to the Food and Drug Administration’s (FDA’s) request for comments on the next cycle of the Prescription Drug […]
2020 National Health Council Policy Matrix
By Maddie Mason, Senior Associate, Policy Each year the National Health Council’s (NHC’s) Board Policy Committee develops a Policy Matrix that is intended to serve as a road map for […]